Genentech, a member of Roche Group, has announced that the FDA has accepted its Biologics License Application and granted priority review for emicizumab, a once-weekly subcutaneous prophylaxis for adults, adolescents, and children with hemophilia A who have factor VIII inhibitors.
Genentech, a member of Roche Group, announced on Wednesday that the FDA has accepted its Biologics License Application (BLA) and granted priority review for emicizumab, a once-weekly subcutaneous prophylaxis for adults, adolescents, and children with hemophilia A who have factor VIII inhibitors. A regulatory decision on the drug is expected by February 23, 2018.
Nearly 1 in 3 patients with hemophilia A, an inherited clotting disorder that affects approximately 20,000 people in the United States, develop inhibitors to standard factor VIII replacement therapies. Development of these inhibitors limits patients’ treatment options and increases the risk of serious bleeds. Emicizumab, an investigational bispecific monoclonal antibody, is designed to bring together factors IXa and X, which are required to activate the natural coagulation cascade and restore the blood-clotting process.
“Genentech has a history of developing innovative antibody therapies to address some of the highest unmet medical needs,” said Sandra Horning, MD, CMO and head of global product development at Genentech. “Results of our [phase 3] study in adults and adolescents as well as early [phase 3] results in children showed that emicizumab has significant potential to help people with hemophilia A with inhibitors, who face major challenges in preventing and treating bleeds.”
Genentech’s BLA for emicizumab is based on the results of the phase 3 HAVEN 1 and HAVEN 2 studies. In the HAVEN 1 study, 62.9% of patients receiving emicizumab experienced zero treated bleeds (compared with 5.6% of patients receiving on-demand bypassing agents) after 31 weeks of emicizumab prophylaxis. Interim results from the single-arm HAVEN 2 study in children under 12 years showed that 1 patient (of 19) receiving emicizumab reported a treated bleed at a median observation time of 12 weeks.
Some analysts suggest that if emicizumab is approved, the novel biologic could generate approximately $1.5 billion in sales for Genentech (and its parent company, Roche) by 2022. Those earnings could offset the potential erosion of its earnings from Roche’s cancer drugs, bevacizumab (Avastin), trastuzumab (Herceptin), and rituximab (Mabthera, Rituxan), which together brought in $22.1 billion in sales in 2016. All 3 blockbuster drugs face oncoming biosimilar competition.
Genentech and Roche’s development of novel biologics also includes other drugs with the potential to earn strong sales numbers. A few other monoclonal antibodies being developed by the 2 companies are currently in phase 3 development, including obinutuzumab, for the treatment of non-Hodgkin’s lymphoma; etrolizumab, for the treatment of ulcerative colitis and Crohn’s disease; gantenerumab, for the treatment of Alzheimer’s disease; and ocrelizumab, for the treatment of multiple sclerosis.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.